Highlights GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:22 13/06/2025 BST			5-day change	1st Jan Change
1,511.50 ^GBX	-2.45%		-0.10%	+12.25%

06-13	Alector, Inc. Announces Chief Financial Officer Changes	CI
06-13	Moderna falls on doubts over new CDC panel's backing of RSV vaccine	RE

Highlights

GSK Says EMA Accepts Application to Expand RSV Vaccine Use to Adults Above 18	06-13	MT
GSK applies to EU regulator for expanded use of RSV vaccine	06-13	RE
UK Stocks-UK Factors to watch on June 13	06-13	RE
GSK plc's RSV Vaccine Accepts for Regulatory Review by the European Medicines Agency to Expand Use in Adults 18 Years and Older	06-13	CI
PHP hits back after Assura backs KKR offer	06-13	AN
GSK says EU heath regulator reviewing expansion of RSV vaccine	06-13	RE
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults	06-13	RE
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults	06-13	RE
US Senators Introduce Bill to Ban Direct-to-Consumer Drug Ads	06-12	MT
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals	06-12	RE
GSK Licenses Shigella Vaccine Candidate to Bharat Biotech	06-12	MT
EMA PRAC's Reviewing Risk Of Encephalitis With Two Varicella Vaccines	06-06	RE
Perrigo Company plc Announces Executive Changes	06-04	CI
GSK launches second tranche of GBP2 billion share buyback	06-04	AN
GSK Kicks Off Second Tranche of GBP2 Billion Buyback	06-04	MT
Global markets live: Tesla, Sanofi, Apple, JPMorgan, Microsoft…	06-02
GSK Says US FDA Accepts for Review Linerixibat New Drug Application for Relentless Itch	06-02	MT
GSK plc announces the US Food and Drug Administration has accepted for review the NDA for linerixibat	06-02	CI
Theravance Shares Rise Premarket on Sale of Trelegy Royalties	06-02	DJ
US FDA accepts new drug application for GSK's liver drug linerixibat	06-02	AN
US FDA Accepts GSK's Cholestatic Pruritus Drug Application for Review	06-02	MT
GSK: to present 60 papers at two conferences	05-30	CF
Scynexis, Inc. Resumes Patient Dosing in Phase 3Io Study	05-28	CI
GSK: early termination of successful Phase III trial	05-28	CF
GSK plc and Spero Therapeutics Announces PIVOT-PO Phase III Study for Tebipenem HBr Starts Early for Efficacy	05-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : Despite its challenges, GSK remains investable

May 21, 2025 at 03:08 pm

GSK CEO on US Expansion, M&A, Drug Pipeline, Trump

January 13, 2025 at 08:03 pm

GSK plc : Back on track

May 03, 2024 at 10:17 am